A citation-based method for searching scientific literature

Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao, Omoniyi J Adedokun, Bruce E Sands, Stephen B Hanauer, Severine Vermeire, Stephan Targan, Subrata Ghosh, Willem J de Villiers, Jean-Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce A Salzberg, Pierre Desreumaux, Scott D Lee, Edward V Loftus, Levinus A Dieleman, Seymour Katz, Paul Rutgeerts. N Engl J Med 2016
Times Cited: 821







List of co-cited articles
740 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J Adedokun, Katherine Li, Laurent Peyrin-Biroulet, Gert Van Assche,[...]. N Engl J Med 2019
342
35

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
29

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
731
25

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
20

Infliximab, azathioprine, or combination therapy for Crohn's disease.
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard,[...]. N Engl J Med 2010
15

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
15

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
660
13

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Stephen B Hanauer, William J Sandborn, Brian G Feagan, Christopher Gasink, Douglas Jacobstein, Bin Zou, Jewel Johanns, Omoniyi J Adedokun, Bruce E Sands, Paul Rutgeerts,[...]. J Crohns Colitis 2020
72
18

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
553
13

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
297
13

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
Marco Daperno, Geert D'Haens, Gert Van Assche, Filip Baert, Philippe Bulois, Vincent Maunoury, Raffaello Sostegni, Rodolfo Rocca, Angelo Pera, Annemie Gevers,[...]. Gastrointest Endosc 2004
897
12

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
12

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D'Amico, Jasbir Dhaliwal, Anne M Griffiths, Dominik Bettenworth, William J Sandborn, Bruce E Sands, Walter Reinisch,[...]. Gastroenterology 2021
236
12

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler,[...]. Lancet 2017
254
12

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik,[...]. J Crohns Colitis 2017
11

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Stephen B Hanauer, Brian G Feagan,[...]. Gastroenterology 2018
114
11

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Vince B C Biemans, C Janneke van der Woude, Gerard Dijkstra, Andrea E van der Meulen-de Jong, Mark Löwenberg, Nanne K de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M Jansen, Alexander G L Bodelier,[...]. Aliment Pharmacol Ther 2020
37
27

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Jean-Frederic Colombel, Douglas C Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary,[...]. Gastroenterology 2018
80
11

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Bruce E Sands, Jingjing Chen, Brian G Feagan, Mark Penney, William A Rees, Silvio Danese, Peter D R Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra,[...]. Gastroenterology 2017
153
9

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G Feagan, Julián Panés, Marc Ferrante, Arthur Kaser, Geert R D'Haens, William J Sandborn, Edouard Louis, Markus F Neurath, Denis Franchimont, Olivier Dewit,[...]. Lancet Gastroenterol Hepatol 2018
86
10

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
William J Sandborn, Brian G Feagan, Edward V Loftus, Laurent Peyrin-Biroulet, Gert Van Assche, Geert D'Haens, Stefan Schreiber, Jean-Frederic Colombel, James D Lewis, Subrata Ghosh,[...]. Gastroenterology 2020
70
11

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Bruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, Silvio Danese, Jean-Frédéric Colombel, Murat Törüner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers,[...]. N Engl J Med 2019
231
8

The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Geert D'Haens, Remo Panaccione, Edward V Loftus, Serap Sankoh, Irving Fox,[...]. Gut 2017
426
8

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Vince B C Biemans, Andrea E van der Meulen-de Jong, Christine J van der Woude, Mark Löwenberg, Gerard Dijkstra, Bas Oldenburg, Nanne K H de Boer, Sander van der Marel, Alexander G L Bodelier, Jeroen M Jansen,[...]. J Crohns Colitis 2020
66
12

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
Hadrien Alric, Aurélien Amiot, Julien Kirchgesner, Xavier Tréton, Matthieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel, Antoine Meyer. Aliment Pharmacol Ther 2020
32
25

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif. Clin Gastroenterol Hepatol 2017
132
8

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Paul Rutgeerts, Gert Van Assche, William J Sandborn, Douglas C Wolf, Karel Geboes, Jean-Frédéric Colombel, Walter Reinisch, Ashish Kumar, Andreas Lazar, Anne Camez,[...]. Gastroenterology 2012
408
8

ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands. Am J Gastroenterol 2018
483
8

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Richmond Sy, Geert D'Haens, Shomron Ben-Horin, Jing Xu, Maria Rosario,[...]. Gastroenterology 2014
426
8

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Gert van Assche, Walter Reinisch, Jean-Frederic Colombel, Geert D'Haens, Douglas C Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B Thakkar. Gastroenterology 2012
782
8

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu'Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger,[...]. Gut 2019
545
8

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
939
8

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf, Paul Pollack. Gastroenterology 2006
8

Infliximab maintenance therapy for fistulizing Crohn's disease.
Bruce E Sands, Frank H Anderson, Charles N Bernstein, William Y Chey, Brian G Feagan, Richard N Fedorak, Michael A Kamm, Joshua R Korzenik, Bret A Lashner, Jane E Onken,[...]. N Engl J Med 2004
8

Crohn's disease.
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Lancet 2017
780
8

Certolizumab pegol for the treatment of Crohn's disease.
William J Sandborn, Brian G Feagan, Simeon Stoinov, Pieter J Honiball, Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber. N Engl J Med 2007
779
8

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky,[...]. Lancet 2017
238
7

Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
Marisa Iborra, Belén Beltrán, Agnes Fernández-Clotet, Eva Iglesias-Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra-Ausin, Francisco Mesonero, Rocío Ferreiro-Iglesias,[...]. Aliment Pharmacol Ther 2020
13
53

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Claire Liefferinckx, Bram Verstockt, Ann Gils, Maja Noman, Catherine Van Kemseke, Elisabeth Macken, Martine De Vos, Wouter Van Moerkercke, Jean-Francois Rahier, Peter Bossuyt,[...]. J Crohns Colitis 2019
45
15

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
W J Sandborn, P Rutgeerts, C Gasink, D Jacobstein, B Zou, J Johanns, B E Sands, S B Hanauer, S Targan, S Ghosh,[...]. Aliment Pharmacol Ther 2018
75
9

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano,[...]. Lancet 2019
93
7

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
7

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison Jess, Pei-Shun Li, Karen Kroeker, Brendan Halloran, Remo Panaccione, Laurent Peyrin-Biroulet,[...]. Clin Gastroenterol Hepatol 2021
24
29

IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Alexander R Moschen, Herbert Tilg, Tim Raine. Nat Rev Gastroenterol Hepatol 2019
156
7

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Jean-Frédéric Colombel, Remo Panaccione, Geert D'Haens, Ju Li, Marie R Rosenfeld, Jeffrey D Kent,[...]. Ann Intern Med 2007
719
7

Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando. Expert Opin Biol Ther 2020
20
30

A simple index of Crohn's-disease activity.
R F Harvey, J M Bradshaw. Lancet 1980
6

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Christopher Ma, Richard N Fedorak, Gilaad G Kaplan, Levinus A Dieleman, Shane M Devlin, Nathan Stern, Karen I Kroeker, Cynthia H Seow, Yvette Leung, Kerri L Novak,[...]. Inflamm Bowel Dis 2017
57
10

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri,[...]. Lancet Gastroenterol Hepatol 2019
235
6

Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Anja Eberl, Taru Hallinen, Clas-Göran Af Björkesten, Markku Heikkinen, Eija Hirsi, Mikko Kellokumpu, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Heikki Nuutinen,[...]. Scand J Gastroenterol 2019
21
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.